Menopause, Female Sex Hormones and Contraception

Connect ovarian hormone physiology with menopausal symptoms, hormone therapy, contraceptive mechanisms and family-planning decisions for rapid KMU revision.

1. THE TOPIC IN ONE CONNECTED FLOW

This topic is centered on control by estrogen and progesterone. Loss of ovarian follicular activity produces menopause and its consequences, while giving estrogen or progestins pharmacologically can replace deficient hormone effects or deliberately alter the hypothalamic-pituitary-ovarian axis to prevent pregnancy. Safe treatment therefore depends on linking hormone action with symptoms, risks and reproductive goals.

Ovarian Hormones

Estrogen + progesterone regulate reproductive tissues and feedback

→

Two Key Changes

Hormone loss in menopause or exogenous hormone administration

→

Functional Effect

Menopause: ↓ estrogen
Contraception: altered FSH/LH, mucus and endometrium

→

Clinical Result

Menopausal symptoms or prevention of ovulation/fertilization

→

Intervention

HRT, oral pills, progestin-only methods, IUDs or emergency contraception

→

Method Selection

Balance effectiveness, risks, reversibility and patient preference

→

Outcome

Symptom control, pregnancy prevention and informed family planning

Hormonal axis connection:
Ovarian follicle depletion → ↓ estrogen and inhibin → ↓ negative feedback → ↑ FSH/LH → menopausal effects.
In contrast, contraceptive estrogen/progestin → increased negative feedback → suppression of follicular development and the LH surge → reduced ovulation.

2. KEY CLINICAL CONNECTIONS

Menopause → Symptoms → HRT Choice

Follicular depletion
→
estrogen deficiency
→
hot flushes, vaginal atrophy and increased bone resorption
→
symptom-directed management.

Systemic estrogen + intact uterus
→
add progestogen
→
reduced risk of endometrial hyperplasia.

Hormonal Contraception → Mechanism → Safety

Estrogen + progestin
→
suppression of FSH/LH
→
inhibition of ovulation
→
effective reversible contraception.

Estrogen exposure
→
hepatic coagulation effects
→
avoid combined methods when major thrombotic or vascular risks are present.

Method Characteristics → Real-World Effectiveness

Daily pills or barrier methods
→
greater dependence on correct use
→
larger typical-use failure.

Implant or IUD
→
minimal daily user action
→
very high contraceptive effectiveness.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ Follicle depletion → ↓ estrogen/inhibin → ↑ FSH → menstrual cessation, vasomotor symptoms and accelerated bone resorption.

Postmenopausal bleeding → possible genital tract pathology → requires evaluation rather than reassurance as a normal menopausal symptom.

⭐ Systemic estrogen + intact uterus → endometrial proliferation → add a progestogen for endometrial protection; estrogen alone is generally reserved for women without a uterus.

Estrogen → intracellular receptor → altered gene transcription; Premarin is conjugated equine estrogen, while progestins act through progesterone receptors.

⭐ Combined pills → negative feedback → suppressed ovulation; progestin also thickens cervical mucus and suppresses the endometrium.

Progestin-only methods → no estrogen exposure → useful when estrogen is unsuitable; mini-pills require adherence, whereas DMPA and implants reduce daily user dependence.

⭐ Emergency contraception → intervention before established pregnancy; oral agents mainly delay ovulation, while the copper IUD strongly impairs sperm function and fertilization.

Family planning → informed contraceptive choice → effectiveness, safety, reversibility and preference affect uptake; misinformation, poor access and limited choice can lower contraceptive prevalence.

AIM Exam Trap: Hormonal contraception does not depend mainly on making the endometrium unsuitable. For combined oral pills, the principal contraceptive mechanism is suppression of ovulation.